| Dr Terri E Kakugawa, DO | |
|
86-260 Farrington Hwy, Waianae, HI 96792-3128 | |
| (808) 696-7081 | |
| (808) 696-7093 |
| Full Name | Dr Terri E Kakugawa |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 32 Years |
| Location | 86-260 Farrington Hwy, Waianae, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154417756 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DOS-726 (Hawaii) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Waianae District Comprehensive Health And Hospital Board, Incorporated | 9931008349 | 113 |
News Archive
Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients.
In anticipation of World Tuberculosis (TB) Day, commemorated on March 24, this Lancet editorial examines TB control and elimination efforts in 2012 and beyond. "Tuberculosis killed 1.45 million people in 2010 and about 500,000 people have drug-resistant disease," the editorial states, adding, "Despite a woeful funding gap in 2012 of $1.7 billion, tuberculosis incidence is falling (from 9.4 million in 2009 to 8.8 million in 2010)."
About 1,300 health officials on Wednesday at the close of the 3rd Stop TB Partnership Forum in Rio de Janeiro, Brazil, said that $44 billion is "needed from now until 2015 to reach" World Health Organization targets aimed at controlling the disease in the 22 countries with the highest TB burden worldwide, AFP/Google.com reports.
Mannatech, Incorporated, a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, obtained a judgment finding that Green Life, LLC (Green Life), and Xiong Lo (Lo) infringed Mannatech patents (U.S. Patents 6,929,807; 7,157,431; 7,196,064; 7,199,104; and 7,202,220).
Peregrine Pharmaceuticals, Inc. today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer.
› Verified 5 days ago
| Entity Name | Waianae District Comprehensive Health And Hospital Board, Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275566424 PECOS PAC ID: 9931008349 Enrollment ID: O20040105000833 |
News Archive
Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients.
In anticipation of World Tuberculosis (TB) Day, commemorated on March 24, this Lancet editorial examines TB control and elimination efforts in 2012 and beyond. "Tuberculosis killed 1.45 million people in 2010 and about 500,000 people have drug-resistant disease," the editorial states, adding, "Despite a woeful funding gap in 2012 of $1.7 billion, tuberculosis incidence is falling (from 9.4 million in 2009 to 8.8 million in 2010)."
About 1,300 health officials on Wednesday at the close of the 3rd Stop TB Partnership Forum in Rio de Janeiro, Brazil, said that $44 billion is "needed from now until 2015 to reach" World Health Organization targets aimed at controlling the disease in the 22 countries with the highest TB burden worldwide, AFP/Google.com reports.
Mannatech, Incorporated, a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, obtained a judgment finding that Green Life, LLC (Green Life), and Xiong Lo (Lo) infringed Mannatech patents (U.S. Patents 6,929,807; 7,157,431; 7,196,064; 7,199,104; and 7,202,220).
Peregrine Pharmaceuticals, Inc. today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Terri E Kakugawa, DO 86-260 Farrington Hwy, Waianae, HI 96792-3128 Ph: (808) 696-7081 | Dr Terri E Kakugawa, DO 86-260 Farrington Hwy, Waianae, HI 96792-3128 Ph: (808) 696-7081 |
News Archive
Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients.
In anticipation of World Tuberculosis (TB) Day, commemorated on March 24, this Lancet editorial examines TB control and elimination efforts in 2012 and beyond. "Tuberculosis killed 1.45 million people in 2010 and about 500,000 people have drug-resistant disease," the editorial states, adding, "Despite a woeful funding gap in 2012 of $1.7 billion, tuberculosis incidence is falling (from 9.4 million in 2009 to 8.8 million in 2010)."
About 1,300 health officials on Wednesday at the close of the 3rd Stop TB Partnership Forum in Rio de Janeiro, Brazil, said that $44 billion is "needed from now until 2015 to reach" World Health Organization targets aimed at controlling the disease in the 22 countries with the highest TB burden worldwide, AFP/Google.com reports.
Mannatech, Incorporated, a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, obtained a judgment finding that Green Life, LLC (Green Life), and Xiong Lo (Lo) infringed Mannatech patents (U.S. Patents 6,929,807; 7,157,431; 7,196,064; 7,199,104; and 7,202,220).
Peregrine Pharmaceuticals, Inc. today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer.
› Verified 5 days ago
Dr. Malia-susanne L Lee, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 86-260 Farrington Hwy, Waianae, HI 96792 Phone: 808-696-7081 Fax: 808-696-7093 | |
Leimomi Kanagusuku, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 86-260 Farrington Hwy, Waianae, HI 96792 Phone: 808-697-3300 | |
Catherine Joanne Simonovich Tsang, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 86-260 Farrington Hwy, Waianae, HI 96792 Phone: 808-697-3300 | |
Christina K.k. Adams, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 86-260 Farrington Hwy, Waianae, HI 96792 Phone: 808-696-7081 Fax: 808-696-7093 | |
Carolina Dominica Davide, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 85-910 Farrington Hwy, Suite 102, Waianae, HI 96792 Phone: 808-696-4044 Fax: 808-696-4009 | |
Jan N. Inao, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 87-2116 Farrington Hwy, Waianae, HI 96792 Phone: 808-441-3500 |